(April 15, 2015) Doctors have long recognized that women with mutations in two particular genes – BRCA1 and BRCA2 – have a higher risk of breast and ovarian cancer. Now they are starting to figure out which mutations are worse than others. They have even discovered that some of these mutations may reduce a woman’s … Continued
(April 14, 2015) The FDA granted breakthrough therapy designation to rucaparib as monotherapy for patients with advanced ovarian cancer. Rucaparib is an oral, small-molecule PARP inhibitor developed for the treatment of platinum-sensitive ovarian cancer, specifically in patients with tumors that have BRCA mutations and other DNA deficiencies commonly referred to as “BRCA-like.” An FDA-designated “breakthrough … Continued
Designer Charity Sale Offers Day-Long Luxury Experiences for the Whole Family Los Angeles, CA (April 14, 2015) – Rachel Zoe and Rodger Berman with Molly Sims and Scott Stuber will return to host Ovarian Cancer Research Fund’s (OCRF) 2nd Annual Super Saturday LA. The day-long designer charity sale, now held annually in Los Angeles as … Continued
We are now accepting letters of intent for all research grants. LOIs are due May 8, 2015. Click here for more information.
In response to the “Angelina Jolie Pitt: Diary of a Surgery,” Op-Ed, published in The New York Times on March 24, 2015, OCRF co-wrote a Letter to the Editor along with Ovarian Cancer National Alliance, reminding readers that there is still no early detection method for ovarian cancer. We’re grateful to once again have the … Continued
(April 2, 2015) According to a study published in the journal Oncogene, the tumor microenvironment can regulate tumor suppressor miRNA in ovarian cancer cells. The direct interaction of the ovarian cancer cells with mesothelial cells, which cover the surface of the omentum, caused methylation mediated decrease in the expression of miR-193b in the tumor cells. … Continued
(April 1, 2015) A study published in Cancer Epidemiology, Biomarkers and Prevention looks at ovarian cancer risk in the general population. In U.S. women, lifetime risk of ovarian cancer is 1.37%, but some women are at a substantially lower or higher ovarian cancer risk due to both genetic and lifestyle factors. Leigh Pierce, PhD and … Continued
Angelina Jolie Pitt recently announced that she has had her ovaries and fallopian tubes removed in order to reduce her risk of ovarian cancer. Ms. Jolie Pitt had previous shared that she has a mutation in the BRCA gene, which increases her risk of breast and ovarian cancers. The Alliance received many calls and requests … Continued
(March 27, 2015) According to research published this week in the Journal of Clinical Oncology, intraperitoneal (IP) chemotherapy is associated with a long-term survival advantage in ovarian cancer. The advantage of IP over intravenous chemotherapy extends beyond 10 years, and IP therapy enhanced survival of those with gross residual disease. Survival improved with increasing number … Continued
The Ovarian Cancer Alliance of Greater Cincinnati (OCAGC) became a Partner Member of the Alliance in October 2010. “It’s been a very positive partnership,” says Martha Farr, an ovarian cancer survivor and co-chair of OCAGC’s Board of Trustees. The group started almost a decade ago, hosting an annual walk to raise awareness. Eventually, the volunteers … Continued
(March 20, 2015) This excellent, accessible piece in Mosaic Magazine, “Decisions on a Knife-Edge,” explores the difficult choices high-risk women face when considering how to decrease their chances of developing ovarian cancer. Removing only the fallopian tubes will avoid forcing a woman into early menopause, which is an appealing option for many women. Yet it’s not … Continued
(March 10, 2015) An algorithm developed at MD Anderson Cancer Center in Houston has dramatically increased complete resection rates in advanced ovarian cancer, giving patients the best possible chance of survival. The work was funded in part by an OCRF research grant to Anil Sood, MD. The results are summarized in an article in Nature … Continued
Get email updates about research news, action alerts, and ways to join the fight.
A global, Al-powered ecosystem designed to transform gynecologic cancer research—connecting patients, researchers, and clinicians to accelerate breakthroughs.
Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.
